Dermata Therapeutics, Inc. (DRMA)
$0.00+$0.00 (+0.00%) TodayExtended Hours
Munera Maria E. Bedoya-Toro - OfficerDermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 1 | 11 | $13 |
| Grant or award | 9 | 4,897,956 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
17 Form 4 filings on record, the earliest from Dec 30, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Gerald T. Proehl - Officer | Grant or award | Common Stock | 170,068 | - | - | |
| Gerald T. Proehl - Officer | Grant or award | Series E Warrant (Right to Buy) | 1,360,544 | - | - | |
| Gerald T. Proehl - Officer | Grant or award | Series F Warrant (Right to Buy) | 1,360,544 | - | - | |
| Gerald T. Proehl - Officer | Grant or award | Series E Warrant (Right to Buy) | 170,068 | - | - | |
| Gerald T. Proehl - Officer | Grant or award | Series F Warrant (Right to Buy) | 170,068 | - | - | |
| Gerald T. Proehl - Officer | Grant or award | Pre-Funded Warrant (Right to Buy) | 1,360,544 | - | - | |
 Hoose Kyri K. van - Officer | Grant or award | Common Stock | 102,040 | - | - | |
| Hoose Kyri K. van - Officer | Grant or award | Series E Warrant (Right to Buy) | 102,040 | - | - | |
| Hoose Kyri K. van - Officer | Grant or award | Series F Warrant (Right to Buy) | 102,040 | - | - | |
| Kathleen D. Scott - Director | Open-market sale | Common Stock | 11 | $1.19 | $13 | |
| Munera Maria E. Bedoya-Toro - Officer | Open-market purchase | Common Stock | 1,000 | $1.27 | $1K | |
| Gerald T. Proehl - Officer | Grant or award | Stock Option (right to buy) | 37,500 | $0.00 | - | |
 David F. Hale - Director | Grant or award | Stock Option (Right to Buy) | 2,500 | $0.00 | - | |
| Wendell Wierenga - Director | Grant or award | Stock Option (Right to Buy) | 2,500 | $0.00 | - | |
| Munera Maria E. Bedoya-Toro - Officer | Grant or award | Stock Option (right to buy) | 9,000 | $0.00 | - | |
| Kathleen D. Scott - Director | Grant or award | Stock Option (Right to Buy) | 2,500 | $0.00 | - | |
 Andrew Seth Sandler - Director | Grant or award | Stock Option (Right to Buy) | 2,500 | $0.00 | - | |
 Christopher J. Nardo - Officer | Grant or award | Stock Option (right to buy) | 18,000 | $0.00 | - | |
 Steven J. Mento - Director | Grant or award | Stock Option (Right to Buy) | 2,500 | $0.00 | - | |
| Hoose Kyri K. van - Officer | Grant or award | Stock Option (right to buy) | 18,000 | $0.00 | - | |
| Mary Fisher - Director | Grant or award | Stock Option (Right to Buy) | 2,500 | $0.00 | - | |
 Brittany Bradrick - Director | Grant or award | Stock Option (Right to Buy) | 2,500 | $0.00 | - | |
| Hoose Kyri K. van - Officer | Grant or award | Common Stock | 122,549 | - | - | |
| Hoose Kyri K. van - Officer | Grant or award | Series C Warrant (Right to Buy) | 122,549 | - | - | |
| Hoose Kyri K. van - Officer | Grant or award | Series D Warrant (Right to Buy) | 122,549 | - | - | |
| Hoose Kyri K. van - Officer | Derivative | Warrant (Right to Buy) | 7,874 | - | - | |
| Hoose Kyri K. van - Officer | Grant or award | Warrant (Right to Buy) | 7,874 | - | - | |
| Gerald T. Proehl - Officer | Grant or award | Common Stock | 490,196 | - | - | |
| Gerald T. Proehl - Officer | Grant or award | Common Stock | 122,549 | - | - | |
| Gerald T. Proehl - Officer | Grant or award | Series C Warrant (Right to Buy) | 490,196 | - | - | |
| Gerald T. Proehl - Officer | Grant or award | Series D Warrant (Right to Buy) | 490,196 | - | - | |
| Gerald T. Proehl - Officer | Grant or award | Series C Warrant (Right to Buy) | 122,549 | - | - | |
| Gerald T. Proehl - Officer | Grant or award | Series D Warrant (Right to Buy) | 122,549 | - | - | |
| Gerald T. Proehl - Officer | Derivative | Warrant (Right to Buy) | 78,740 | - | - | |
| Gerald T. Proehl - Officer | Grant or award | Warrant (Right to Buy) | 78,740 | - | - |
Dermata Therapeutics, Inc. (DRMA) had 3 insider filings in the last 90 days, with the most recent on 2026-08-18. The full record for DRMA runs to 17 Form 4 filings, the earliest from 2025-12-30. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of DRMA were filed in the last 90 days. 1 purchase is on record for this company.
1 insider sale of DRMA was filed in the last 90 days, totaling $13.
This page tracks DRMA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add DRMA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
$DRORDror Ortho-Design, Inc.
$DRTSAlpha Tau Medical Ltd.
$DRUGBRIGHT MINDS BIOSCIENCES INC.
$DSACDaedalus Special Acquisition Corp.
$DSCDSC Holdings Ltd.
$DSCRXDiamond Hill Securitized Credit Fund
$DSLDoubleLine Income Solutions Fund
$DSMBNY MELLON STRATEGIC MUNICIPAL BOND FUND, INC.
$DSNYDESTINY MEDIA TECHNOLOGIES INC
$DSUBLACKROCK DEBT STRATEGIES FUND, INC.Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.